Date Added: 20/03/2017
Date Updated: 20/03/2017
DNX-2401 for recurrent glioblastoma – in combination with pembrolizumab
Specialties: Oncology & radiotherapy
Technology Type: Drugs
Stage of development: Experimental - pilot or phase II
Stage of EAA: Prioritised for assessment
Glioblastoma or gliosarcoma tumour: recurrent; where gross total resection is not possible or advisable – second line; in combination with pembrolizumab.
DNX-2401 (adenovirus-5 delta 24 RGD; ad-delta24-RGD; Ad-DNX 2401; IE-CRAd; RGD-delta24; VLI-01A) uses a genetically modified adenovirus genome to replicate selectively in retinoblastoma-pathway (Rb) deficient cells. DNX-2401 triggers tumour cell necrosis and intratumoural immune cell infiltration. Replicated copies of DNX-2401, tumour antigens and immune factors are released on cell lysis, stimulating continued tumour response.